Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study
S-1 monotherapy demonstrated comparable effectiveness and manageable toxicity in real-world settings, with significantly better outcomes when used as first-line or second-line treatment in NSCLC.
Authors
- I-Lin Tsai
- Yueh‐Fu Fang (ORCID: https://orcid.org/0000-0003-2211-3076)
- Chih‐Hsi S. Kuo (ORCID: https://orcid.org/0000-0003-3309-937X)
- Ching‐Fu Chang (ORCID: https://orcid.org/0000-0001-5219-6357)
- Chenyang Huang (ORCID: https://orcid.org/0000-0002-1956-6229)
- Ping‐Chih Hsu (ORCID: https://orcid.org/0000-0003-0173-7509)
- Po‐Lan Su (ORCID: https://orcid.org/0000-0002-8470-6590)
- John Wen‐Cheng Chang (ORCID: https://orcid.org/0000-0001-8373-5691)
- Chien‐Chung Lin (ORCID: https://orcid.org/0000-0001-9766-2083)
- Cheng-Ta Yang (ORCID: https://orcid.org/0000-0001-8256-2477)
- Chiao‐En Wu (ORCID: https://orcid.org/0000-0002-1081-8805)
- Chien‐Yu Lin
Institutions
- Chang Gung University (TW)
- Linkou Chang Gung Memorial Hospital (TW)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1177/11795549251348367
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00